Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wai Chun Bio-Technology Ltd. ( (HK:0660) ) just unveiled an announcement.
Wai Chun Bio-Technology Limited reported that all resolutions put to shareholders at its 30 December 2025 annual general meeting were approved by poll, with 129,789,160 shares voted and 100% support recorded for each item. Investors endorsed the audited financial statements for the year ended 30 June 2025, re-elected three independent non-executive directors, reappointed McMillan Woods (Hong Kong) CPA Limited as auditor, and renewed general mandates allowing the board to issue up to 20% and repurchase up to 10% of the company’s share capital, as well as extend the issuance mandate by the amount of shares repurchased. The unanimous backing strengthens the board’s flexibility in capital management and governance, signaling solid shareholder support for the company’s current direction and giving management wider scope to undertake future equity and buy-back activities.
More about Wai Chun Bio-Technology Ltd.
Wai Chun Bio-Technology Limited is a Hong Kong-listed company incorporated in the Cayman Islands, operating in the bio-technology sector. Its shares are traded on the Main Board of the Stock Exchange of Hong Kong under stock code 660, with a shareholder base that actively participates in corporate governance through annual general meetings.
Average Trading Volume: 95,935
Technical Sentiment Signal: Hold
Current Market Cap: HK$32.84M
See more data about 0660 stock on TipRanks’ Stock Analysis page.